Piper Jaffray Upgrades Seattle Genetics (SGEN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
October 30, 2015 1:12 PM EDTNeedham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) fallowing the company's 3Q earnings results. Adcetris reported record quarterly sales of $59 million, following the company's label expansion into post transplant Hodgkin's lymphoma (HL).
Analyst Chad Messer commented, "Following... More
Seattle Genetics (SGEN) Misses Q3 EPS by 1c
October 29, 2015 4:17 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $84.1 million versus the consensus estimate of $82.67 million.
ADCETRIS sales in the third quarter of $59.1 million, an increase from $48.2 million in the third... More
